Products for Research Use Only
RegisterLogin

LXW7

CAT: 0804-HY-P0178-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P0178-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect[1][2][3].
CAS Number
1313004-77-1
UNSPSC
12352209
Hazard Statement
H302, H315, H319
Target
Integrin
Type
Peptides
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lxw7.html
Purity
99.02
Solubility
H2O
Smiles
O=C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@H](CC(O)=O)C(N[C@@H]1C(C)C)=O)=O)=O)=O)=O)[C@@H](CSSC[C@H](C(N)=O)NC1=O)N
Molecular Formula
C29H48N12O12S2
Molecular Weight
820.89
Precautions
H302, H315, H319
References & Citations
[1]Xiao W, et al. The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol Cancer Ther. 2010 Oct;9 (10) :2714-23.|[2]Fang T, et al. LXW7 ameliorates focal cerebral ischemia injury and attenuates inflammatory responses in activated microglia in rats. Braz J Med Biol Res. 2016 Aug 1;49 (9) :e5287.|[3]Hao D, et al. Discovery and Characterization of a Potent and Specific Peptide Ligand Targeting Endothelial Progenitor Cells and Endothelial Cells for Tissue Regeneration. ACS Chem Biol. 2017 Apr 21;12 (4) :1075-1086.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported

Alternative Products

CatalogName
MBS5763717LXW7
TP2148-01LXW7 TFA (1313004-77-1 free base)

Popular Products